Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs (VIPomas) not responsive to any other therapi...
Saved in:
Main Authors: | Turgut Bora Cengiz, Raksha Kulkarni, Virginia Corbett, Nasrin V. Ghesani, Edward Wolin, Munir V. Ghesani |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1432758/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcome of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Progressive Metastatic Neuroendocrine Tumors from a Tertiary Care Center
by: David Mathew, et al.
Published: (2024-12-01) -
Does treatment with somatostatin analogs differ in the uptake of normal target organs and malignant lesions on 68Ga-DOTATATE PET/CT imaging?
by: Çağlagül Erol, et al.
Published: (2022-08-01) -
Imply on diagnosis and early prognosis of preoperative [68Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumours of glial origin
by: K. Pełka, et al.
Published: (2025-01-01) -
Impact of 68Ga-FAPI positron emission tomography/computed tomography on staging and tumor management in patients with gastric cancer
by: Shunyu Zhang, et al.
Published: (2025-01-01) -
68Ga-Pentixafor PET/CT for the assessment of therapeutic outcomes following superselective adrenal arterial embolization in patients with primary aldosteronism
by: MengDan Li, et al.
Published: (2025-01-01)